Daiichi Sankyo Co. Ltd. has unveiled further reorganization of its vaccines activities in Japan, as it appears to be de-emphasizing the field amid a strategic pivot towards oncology and generic challenges to olmesartan, its former top-selling antihypertensive.
The major Japanese pharma company said that its Kitasato Daiichi Sankyo Vaccine (KDSV) subsidiary would be folded into the parent as of April next year
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?